Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PAOG Targets September 2021 To Introduce CBD Nutraceuticals To Market Co-Packed By ALKM and Marketed Through USMJ
Symbols: PAOG, ALKM, USMJ, KALY
InvestorsHub
Date: March 16, 2021
Sandusky, OH -- March 16, 2021 -- InvestorsHub NewsWire -- PAO Group, Inc. (USOTC: PAOG) today released details on the company’s nutraceutical developments initiative following last week’s introduction of adding CBD RELAX-RX to existing CBD RespRx developments. The details today are highlighted by the company’s September 2021 go-to-market target date with nutraceutical co-packing to be conducted by Alkame Holdings, Inc. (USOTC: ALKM) and product marketing to be conducted by North American Cannabis Holdings, Inc. (USOTC: USMJ).
PAOG is building a comprehensive CBD nutraceuticals strategy to enhance its long-term CBD pharmaceutical strategy. Management recognizes the long-term, investment and research intensive nature of developing a pharmaceutical product and has added the nutraceutical strategy to accelerate the company’s opportunity to achieve revenue starting in 2021.
Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT."
PAOG anticipates soon announcing new breakthroughs in its CBD RespRx pharmaceutical research.
PAOG is on track to introduce its first two CBD nutraceutical products in September of this year, 2021. One CBD nutraceutical product will target the COPD market and the second will target the anxiety and depression market.
In addition to PAOG’s ongoing CBD nutraceutical technical developments in Puerto Rico, PAOG expects to soon announce an additional research partnership to accelerate and expand its CBD developments initiative.
PAOG is working closely with ALKM and USMJ to package and market its first two CBD nutraceutical products and anticipates a number of announcements between now and September to introduce packaging and marketing progress and prepare the market for the September product launch.
Learn more about PAOG at www.paogroupinc.com.
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.
CONTACT INFORMATION
Contact Us:
Jim DiPrima
888-272-6472
info@pao.group
"They" can't keep this one down forever! It is going to blow up very soon. Financials come out, good to go!
PURA and PAOG Confirm Ongoing And Expanding Cannabis Partnership
Symbols: PURA, PAOG, ALKM, USMJ
Dallas, TX -- March 11, 2021 -- InvestorsHub NewsWire -- Puration, Inc. (USOTC: PURA) and PAOG Group, Inc. (USOTC: PAOG) today confirmed the two companies continue to work together on developing a variety of cannabis centric applications through a partnership that initiated when PAOG acquired PURA’s cannabis cultivation business last year.
The PURA and PAOG partnership includes a pending distribution of PAOG stock to PURA shareholders. PURA shareholders are intended to receive one share of PAOG for every PURA share they hold. The intended distribution has been submitted for review by FINRA. Once the review process is complete, PURA and PAOG plan to promptly proceed with the intended distribution.
Operationally, PURA and PAOG are working together on PURA’s Farmersville Brands project. PURA with PAOG’s help, is building a 70-acre facility designed to provide interactive, demonstrable education on the potential of hemp to provide environmentally sustainable alternatives to over $1 trillion in existing industrial products and services currently damaging the environment.
The 70-acre facility is the cornerstone of PURA’s overall Farmersville Hemp Brand strategy designed to accelerate the overall market growth of hemp derived products beyond the industry forecasted 2027 $15 billion market size.
PAOG is specifically partnering with PURA in Farmersville on the construction and operation of indoor, pharmaceutical grade, hemp growing facilities, and the construction and operation of a cannabis extraction lab.
PURA and PAOG are joined on the Farmersville project by North American Cannabis Holdings, Inc. (USOTC: USMJ) and Alkame Holdings, Inc. (USOTC: ALKM) in PURA’s Farmersville Hemp Brand strategy.
For more information on Puration, visit http://www.purationinc.com
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800) 861-1350
Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that Alkame will achieve significant sales, the failure to meet schedule or performance requirements of the Company's contracts, the Company's liquidity position, the Company's ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
PAOG Announces Save The Date For CBD Nutraceuticals Expansion Update
Symbols: PAOG, ALKM, USMJ, KALY
Sandusky, OH -- March 10, 2021 -- InvestorsHub NewsWire -- PAO Group, Inc. (OTC Pink: PAOG) today encouraged all interested to save the date, Tuesday, March 16, 2021, when PAOG will publish details on the company's CBD RELAX-RX nutraceutical development plans including intended co-packing with Alkame Holdings, Inc. (OTC Pink: ALKM) and marketing with North American Cannabis Holdings, Inc. (OTC Pink: USMJ).
CBD RELAX-RX targets the anxiety and depression treatment market anticipated to reach a value of $18 billion by 2025.
The company recently announced plans to produce a variety of CBD nutraceuticals for additional applications beyond the current focus on care for those experiencing issues associated with Chronic Obstructive Pulmonary Disorder (COPD).
Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT."
PAOG plans to develop and distribute its overall CBD nutraceuticals with Alkame Holdings, Inc. (OTC Pink: ALKM) as a copacker and North American Cannabis Holdings, Inc. (OTC Pink: USMJ) as a distributor.
Learn more about PAOG at www.paogroupinc.com.
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.
CONTACT INFORMATION
Contact Us:
Jim DiPrima
888-272-6472
info@pao.group
With all the news surrounding this stock, we are headed for uncharted territory!
ALKM Signals BUY
Symbol: ALKM
March 10, 2021 -- InvestorsHub NewsWire -- via AmericanBulls.com -- Alkame Holdings (ALKM) Singal Update:
Our system’s recommendation today is to BUY. The BULLISH THREE INSIDE UP pattern finally received a confirmation because the prices crossed above the confirmation level which was at 0.0029, and our valid average buying price stands now at 0.0040.
The green light is on and this security is now screaming BUY. It is action time! The bullish pattern that was previously identified is finally confirmed and a BUY signal is generated. Most probably, it is the right time to participate in bullish fervor. Do not miss this bullish opportunity.
Source - https://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=ALKM
Alkame Holdings, Inc. Shares Soar On Potential Co-Packing Deal For (PAOG) CBD RELAX-RX
InvestorsHub
Date: March 10, 2021
Symbols: ALKM, PAOG, USMJ, PURA
March 10, 2021 -- InvestorsHub NewsWire -- via MarketWatch -- Alkame Holdings, Inc. (OTC PINK: ALKM) shares soared on Tuesday after news broke that the company is the likely co-packer for PAO Group, Inc.'s (OTC Pink: PAOG) CBD RELAX-RX nutraceutical product. The anticipated deal is also expected to leverage North American Cannabis Holdings, Inc.'s expertise (OTC Pink: USMJ) to help market the product.
The deal can be substantial, and investors reacted by sending ALKM shares higher by 38% on Tuesday after evaluating the potential impact the agreement could have on near-term revenue growth. CBD RELAX-RX is targeting the anxiety and depression treatment market, which is expected to deliver to the partnership group an $18 billion market opportunity by 2025. PAOG closed 38% higher on the day.
The news on Tuesday extends ALKM's relationship with PAO Group, which is planning to develop and produce a variety of CBD nutraceuticals to treat multiple patient indications. Their initial focus is to create a CBD-based therapeutic for those experiencing issues associated with Chronic Obstructive Pulmonary Disorder (COPD). According to past releases, PAOG plans to use ALKM's co-packing expertise to bring those efforts to commercialization.
The surge in price yesterday follows impressive gains made after ALKM announced advances to its proprietary water treatment technology.
Momentum Continues In March
The massive gain on Tuesday follows the impressive 7% spike made last week after ALKM announced the expansion of its proprietary water treatment technology. The increase there came after the company said it completed research and development stages for the enhanced technology and has filed for patent protection with the United States Patent office.
The strategic pieces are lining up well for ALKM in 2021. Not only are the potential agreements with PAOG a possible revenue-generating game-changer for the company this year on the co-packing side, but its significant advances in its proprietary functional water technology also add to the value proposition. ALKM noted that it has streamlined and improved its water manufacturing processes, resulting in a fluoride-free, alkaline water with a lower oxidation-reduction potential (ORP) and its highest-ever oxygen content. The result is a "good-for-you" water that has been shown to aid in lactate clearance after exercise, toxin removal, and decreased recovery times.
The co-packing deals are channeled through ALKM's wholly-owned subsidiary West Coast Co-Packer, Inc., which has also been busy. At the end of February, an announcement highlighted its initial purchase order for Handout Protection hand sanitizer and wash combo single-use packets. That agreement was made with their Canadian Personal Protection Equipment (PPE) distributor, TheraProducts Canada, Inc. Expectations are that product sales will continue to grow.
In fact, Handout Protection could qualify as a best-in-class product after demonstrating effectiveness in killing known COVID-19 strains and the new coronavirus variants known to spread 50% quicker than COVID-19. Moreover, it's one of the few portable hand wash and sanitizer packets that allow people to wash and sanitize their entire hand.
Better still, unlike traditional wipes, Handout Protection enables users to clean not only their palms but also the tops and sides of the hands, including the fingers, under the nails, and up to the wrist to fight and kill bacteria and germs. And, even as the pandemic gets put under control, it is unlikely that demand for effective sanitizing and germ-killing products will decline. That's excellent news for ALKM.
Additional Opportunities In-Play
Several opportunities are in play for 2021. Already, ALKM is expecting to generate value through its exposure to health and wellness products, its aquaculture water treatment division, an interest in CBD co-packing services, and its plans to enter the billion-dollar pet health and wellness sector. A potentially huge deal in development could have the company exploit the massive opportunities developing in the industrial-use hemp markets. That focus aligns ALKM with other publicly traded companies.
Other deals can accelerate near-term growth. An agreement with PAO Group, Inc., for instance, positions ALKM to capitalize as the co-development and distribution partner for PAOG's emerging nutraceutical product line. Another deal brings the company together with North American Cannabis Holdings, Inc. (OTC Pink: USMJ) to revitalize its interests and investments in the cannabis and CBD space. ALKM is expected to benefit from several recently announced USMJ initiatives that target broad opportunities in the cannabis sector. Details on that partnership are expected soon.
Current projects have ALKM, through West Coast Co-Packer, Inc., expanding its agreements with Puration, Inc. (OTC Pink: PURA) to enhance its services as the bottler of EVERx CBD-infused Sports Water. There, ALKM is taking action to grow the partnership and collaborate to market multiple new CBD-infused consumer products. The two are already planning to develop, produce, and test market a CBD-infused liquid sugar and a CBD pet food supplement. Other products in the early development stages include CBD-infused consumer products and hemp-derived beverages and edibles. Keep in mind that PURA announced that sales of EVERx CBD-infused should surpass $2 million in 2020. That report is imminent and reflects well on ALKM as its bottler.
From an investor's perspective, the best news about ALKM is that they appear to be positioned to deliver value on a near and long-term scale. Thus, while investor's wait on long-term development projects, they still benefit from growth through PURA's EVERx and PAOG's nutraceutical and CBD-based initiatives in the near term. Moreover, their patent-pending technologies can also bring value through licensing opportunities.
Notably, there is a tremendous amount of untapped inherent value from its more than ten subsidiaries and ALKM's willingness and ability to seek out and benefit from emerging opportunities. Therefore, the spike in price on Tuesday may be a prelude to more significant moves to come. After all, with multiple shots on goal in billion-dollar markets, ALKM is positioned for numerous catalysts that could deliver exponential returns.
Disclaimers: Hawk Point Media is responsible for the production and distribution of this content. Hawk Point Media is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available by Hawk Point Media is not intended to be, nor does it constitute, investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report and publication. In no event shall Hawk Point Media be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by Hawk Point Media, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Hawk Point Media was compensated three-thousand-five-hundred-dollars by wire transfer to produce research, video, email, newsletters, and editorial commentary for Alkame Holdings, Inc. by a third party. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. Hawk Point Mediastrongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
Media Contact
Company Name: Hawk Point Media
Contact Person: Jake Ellis
Email: Send Email
City: Miami Beach
State: Florida
Country: United States
Website: https://www.greenlightstocks.com
Source - MarketWatch https://www.marketwatch.com/press-release/alkame-holdings-inc-shares-soar-on-potential-co-packing-deal-for-cbd-relax-rx-2021-03-10
ALKM Vol Alert On VERY BULLISH Signal With PAOG and USMJ News - $0.01 Breakout Potential
Symbols: ALKM, PAOG, USMJ, HCMC
March 9, 2021 -- InvestorsHub NewsWire -- via PennyMillions
ALKM Signals VERY BULLISH At $0.002- Poised To Break Through $0.01?
UPDATE: This is an update to a VERY BULLISH signal announcement released earlier today:
Alkame Holdings, Inc. (USOTC: ALKM), in addition to signaling VERY BULLISH is experiencing high volume trading. At almost 200 million shares as of this writing, ALKM is one of the top 50 most actively traded stocks today on OTC Markets. The high trading volume combined with the VERY BULLISH signal positions ALKM for a potential retesting and breakthrough of a recent $0.01 PPS.
Earlier today, PAOG Group, Inc. (PAOG) published news on working with ALKM and North American Cannabis Holdings, Inc. (USMJ) on a new CBD Nutraceutical Product.
Original Release:
Alkame Holdings, Inc. (USOTC: ALKM) is reported today by BullishInvestor to be signaling VERY BULLISH (bullihsinvestor.com/ALKM). ALKM is the go-to co-packer to multiple cannabis product companies to include Puration, Inc. (PURA), PAO Group, Inc. (PAOG) and North American Cannabis Holdings, Inc. (USMJ), to mention only a few. The ALKM PPS recently tested the $0.01 level and could be ready now to breakthrough.
Source - https://www.pennymillions.com/blog/alkm-signals-very-bullish-at-0002-poised-to-break-through-001
PAOG- PAO Group Inc's Shares Rally; Investors Embrace Its Innovative Therapeutics And Its Revenue-Generating Partnerships
Symbols: PAOG, PURA, USMJ, ALKM
Date: March 9, 2021
March 9, 2021 -- InvestorsHub NewsWire -- via MarketWatch -- PAO Group, Inc.'s (USOTC: PAOG) stock has been trading in sympathy with the broader OTC markets...lower. But a green session on Friday, followed by a roughly 37% move higher on Monday, shows that when investors embrace risk back into their portfolios, PAOG can be a standout performer.
In fact, while its 2-day performance was strong, those gains appear to link to recent updates that legitimize the bullishness. There, PAOG has highlighted plans that are already in motion designed to accelerate revenue growth in the coming quarters. Of note, PAOG is already a revenue-generating company and expects that milestone to continue during the next six quarters.
Better still, as a revenue-generating company, PAOG is not only performing better than hundreds of nano-cap peers but also may be doing as well as some CBD-focused mid-caps that are yet to get a product to market. And while PAOG's $300,000 in revenues from its cannabis cultivation subsidiary have sent share prices higher, more exponential gains can come when PAOG proves to shareholders that it can leverage its revenues to capitalize on emerging opportunities in the CBD and nutraceuticals markets. Several deals are helping to make that happen.
Its RespRx acquisition could lead the growth.
Partnerships, Acquisitions, And Patented Assets Set Up 2021
Shareholders sent shares higher in 2020 after PAOG announced its acquisition of RespRx. That asset enables PAOG to accelerate its initiatives to develop CBD alternatives to treat patients with symptoms associated with Chronic Obstructive Pulmonary Disorder (COPD). But, while investors wanted rapid program development, the Trump administration slowed things down for the entire sector. CBD-based therapeutics was simply not high on his political agenda.
Thus, when markets rotated, and CBD-based therapeutics were less focused on, the sector's smaller stocks took significant hits to their valuations. That was terrible news for PAOG. However, the excellent news now is that PAOG is now better positioned to advance its strategic initiatives compared to 2020.
Undoubtedly, when PAOG acquired RespRx from Kali-Extracts, it was viewed as a potentially transformative acquisition. That's still the case. And while the pace of development has slowed until now, RespRx remains a tremendous asset that can be commercialized to target multiple indications where a better and safer standard of care is needed.
Still, it's important to remember that developing treatments for multiple indications is costly and timely. Investors in "big pharma" wait years after a drug trial is announced to get results, and many times, even after several years of waiting, those drug trials can't advance out of a phase 2 trial. The same patience needs to be afforded to PAOG. Investors should also keep in mind RespRx, and its patented cannabis extraction process could be money-makers without the need to bring a single product to market. In fact, comments made by the inventor of the extraction process said that his method was professionally recognized as producing better quality CBD extracts than GW Pharma (GWPH), a leading company that was purchased by Jazz Pharma for $7.2 billion last February. That quality could lead to licensing, partnerships, and collaborative agreements.
And GW Pharma, by the way, is an example of a company that spent years going against the grain, had big pharma gunning for them, and still proved that CBD-based therapeutics could play a vital role in treating a variety of patient conditions. In turn, one of the "big pharma" that may have criticized the science instead embraced it with a multi-billion dollar purchase.
Better still, PAOG is entering 2021 with multiple shots on goal. In fact, beyond its COPD pharmaceutical initiatives, PAOG is advancing a nutraceutical product line that they believe will compete effectively against already marketed, higher-priced brands.
Nutraceuticals Can Be A Game-Changer
There, PAOG announced engaging with the Puerto Rico Consortium for Clinical Investigation (PRCCI) to assist with developing its proprietary Cannabidiol (CBD) extract into a nutraceutical product. The agreement adds credibility and sector expertise to the initiative and can help expedite approval if the two successfully develop an effective CBD-based treatment to target COPD's debilitating effects.
The goal is to develop CBD-based treatments to replace addictive and often harmful prescription drugs. And as CBD-based therapeutics become more mainstream, the company hopes to receive fast-track review and approval from regulatory agencies acceptance of CBD and cannabinoid compounds as viable and effective treatment options.
Other deals are in place to push its CBD nutraceutical operations. In a multimedia presentation, PAOG detailed its CBD nutraceutical development expansion plans and explained how strategic engagements with Puration, Inc. (USOTC: PURA), North American Cannabis Holdings, Inc. (USOTC: USMJ), and Alkame Holdings, Inc. (USOTC: ALKM) can accelerate growth in multiple directions.
In fact, the breadth of news is keeping investors interested in the stock, and despite recent sector-wide weakness, PAOG has been able to hold its roughly 300% share price increase since the start of the year.
The trend higher is likely to continue when risk makes its way back into the markets. At current share prices, the opportunity may be significant.
Video Link: https://www.youtube.com/embed/p48PfDlIABQ
Partnerships And New Revenues
Perhaps the not-so-hidden gem in all of the discussion is that PAO Group is doing what most of its peers are not doing...generating revenues. And that metric puts the company in an enviable position to capitalize on new opportunities and develop its existing pipeline.
Also, a deal with Alkame Holdings Inc. (OTC PINK: ALKM) to develop and distribute its CBD nutraceuticals adds depth to its commercialization plans and strengthens the operations' logistical side. In other words, PAOG has a distribution infrastructure already in place that can streamline costs and accelerate commercialization later. Another deal with North American Cannabis Holdings, Inc. (OTC Pink: USMJ), which is expected to take on the distributor's role, completes the distribution circle.
The message that PAOG makes to its investors is to respect the time needed for development. CBD-based medicine is a new science despite the numerous headlines, and its popularity and billion-dollar market opportunities send a clear message- CBD-based therapeutics are the real deal.
Allow 2021 To Develop
Thus, PAOG has the same opportunities as other development-stage companies. Moreover, they have a crucial asset in RespRx and are generating revenue to help push programs forward. Also noteworthy is that PAOG is making strategic deals with industry companies that can expedite program development, add to its existing revenues stream, and position it to leverage its patented CBD extraction process to capitalize on substantial market opportunities.
Therefore, given time, PAOG can capitalize on its assets and transform itself from the development-stage to a commercialization-stage company. And in 99.99% of situations, that transformation leads to exponential returns. Sometimes, it just takes time.
Disclaimers: Hawk Point Media is responsible for the production and distribution of this content. Hawk Point Media is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available by Hawk Point Media is not intended to be, nor does it constitute, investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report and publication. In no event shall Hawk Point Media be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by Hawk Point Media, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Hawk Point Media was compensated three-thousand-five-hundred-dollars by wire transfer to produce research, video, email, newsletters, and editorial commentary for PAO Holdings Group, Inc.. by a third party. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. Hawk Point Media strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
Media Contact
Company Name: Hawk Point Media
Contact Person: Jake Ellis
Email: Send Email
City: Miami Beach
State: Florida
Country: United States
Website: https://www.greenlightstocks.com
Source - MarketWatch https://www.marketwatch.com/press-release/pao-group-incs-shares-rally-investors-embrace-its-innovative-therapeutics-and-its-revenue-generating-partnerships-2021-03-09
I am still buying it up!
ALKM Signals VERY BULLISH At $0.002- Poised To Break Through $0.01?
Date: March 9, 2021
Symbols: ALKM, PURA, PAOG, USMJ
March 9, 2021 -- InvestorsHub NewsWire -- via pennymillions --
Alkame Holdings, Inc. (USOTC: ALKM) is reported today by BullishInvestor to be signaling VERY BULLISH (bullihsinvestor.com/ALKM). ALKM is the go-to co-packer to multiple cannabis product companies to include Puration, Inc. (PURA), PAO Group, Inc. (PAOG) and North American Cannabis Holdings, Inc. (USMJ), to mention only a few. The ALKM PPS recently tested the $0.01 level and could be ready now to breakthrough.
Source: pennymillions
PAOG Announces RELAX-RX Nutraceutical For $18 Billion Anxiety And Depression Treatment Market
Symbols: PAOG, KALY, ALKM, USMJ
Date: March 8, 2021
Sandusky, OH -- March 8, 2021 -- InvestorsHub NewsWire -- PAO Group, Inc. (USOTC: PAOG) today announced initiating the development of its new nutraceutical, RELAX-RX, targeting the anxiety and depression treatment market anticipated to reach a value of $18 billion by 2025.
The company recently announced plans to produce a variety of nutraceuticals for additional applications beyond the current focus on care for those experiencing issues associated with Chronic Obstructive Pulmonary Disorder (COPD).
Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT."
PAOG plans to develop and distribute its CBD nutraceuticals with Alkame Holdings, Inc. (OTC Pink: ALKM) as a copacker and North American Cannabis Holdings, Inc. (OTC Pink: USMJ) as a distributor.
Learn more about PAOG at www.paogroupinc.com.
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.
CONTACT INFORMATION
Contact Us:
Jim DiPrima
888-272-6472
info@pao.group
I feel the same way. I have good feelings about this one. Also the data backs it up. We will get back up to where this stock should be, in at least penny land.
Very true, get them cheap while you still can!
Agreed, I am adding as I can. Just added another 70,000
I think I will buy more of this "fake" stock also! LOL
Good news. They are on the right path to success! Buying it up!
Agreed. I learned a long time ago not to allow emotions into investing, or trading. We will be good, this is a long term hold.
Agreed, there is a lot going on with ALKM, just because the stock is down, does not mean it is not a good company, with long term potential. It will go back up. Now is a great time to get some cheep shares.
What is a stock "Scan"?
Ah, that news. That is great to hear. Let's ride this baby!
What news? Link?
Yes, exactly what I am doing. This will blow soon and I want to be on board!
I am still buying as I get more money in my account. I know this will continue the upward tread it has been on. Good things are coming with this one!
LOL, yeah, I have made a lot of money on this stock over the years! Now I am in it long term.
Slow and steady, that is what I want to see. Solid growth that can be built upon. That whole idea of a solid foundation, right?
Buying as much as I can on my limited budget! I know this is going to be a good one. I am in it for the long haul.
Continuing to buy! I know this one is good long term.
I agree, and am really looking forward to the continued growth of this company. I could see them being a $10 and up stock in the not too distant future.
I have been in this stock for 5 years now, and have been on here the whole time. I have been reading what all of you have been saying for years.
Now I figured I would join the conversation.
I have traded this a lot over the years, and today I tripled my holdings!
I have also done a lot of research, and can honestly say that I have faith that this company will do very well, and become viable as a serious company. I am enjoying the ride.